Conversations on 
Twitter :
-
Risk of Tweeting? Some harsh analyst words for Horizon Pharma CEO after Q2 announcement.
Analyst response to Horizon CEO Tweet - Another example of Twitter as a dissection platform: Biotech analysts get into details of Complete Genomics' financial disclosures.
@FierceBiotech: Nanomaterial propels animals' heart attack-damaged hearts to repair themselves. Article | Follow @FierceBiotech
@JohnCFierce: Sen. Gillibrand wants to create a $200M marketing fund for biotechs. From petri dish to marketplace? Report | Follow @JohnCFierce
@RyanMFierce: Orbimed has backed Intercept Pharma in a $30M C round with lead drug for primary biliary cirrhosis. Release | Follow @RyanMFierce
> Novo Nordisk ($NVO) chief scientist Mads Krogsgaard tells Reuters, unsurprisingly, that without really good results from a Phase III study of the company's hemophilia candidate, vatreptacoq alfa, the blockbuster program will be dropped. Article
> Hungry for funding after reorganizing key partnerships, Infinity Pharmaceuticals ($INFI) has priced an offering of 5.3 million shares for $14.50 per share. Item
> U.S. Sen. Kirsten Gillibrand talked up a proposed bill that would create a bank aimed at providing universities with funding to commercialize discoveries and create jobs in industries such as biotech. Report
> Drug developer Galenea expanded its alliance with the CHDI Foundation to continue research of new drugs for Huntington's disease. Release
> Computers help researchers tackle drug-resistant bugs. Abstract
Pharma News
@FiercePharma: Special reports this week: Top 11 Fastest-Growing Generics Companies | Top 10 Drug Advertising Spends -- Q1 2012. | Follow @FiercePharma
> New statins study sorts out diabetes risks. More
> Roche blockbuster Avastin does well as brain tumor therapy. Story
> Forest board yields in investor lawsuits. Article
> Generic cream price spikes have experts scratching their heads. Report
@FierceMedDev: St. Jude's recalled Riata leads get slapped again. News | Follow @FierceMedDev
@MarkHFierce: BG Medicine has pulled a 510(k) filing for a cardiac disease test. Shockingly, investors weren't happy. Story | Follow @MarkHFierce
@DamianFierce: Despite losing $7M on three recalls, CareFusion posted an income boost for fiscal Q4. News | Follow @DamianFierce
> Luminex scores $11.6M deal for biothreat Dx. Article
> Exact Sciences seeks $50.2M in public offering. More
And Finally… The U.K.'s humble answer to Warren Buffett has written a new book that explores the future of biotech and the impact of computer-aided genomics research. Item